Pharmanutra SpA (PHNU)

Currency in EUR
77.60
+0.10(+0.13%)
Closed·
Earnings results expected in 3 days
PHNU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
77.2079.40
52 wk Range
38.7583.30
Key Statistics
Prev. Close
77.5
Open
79
Day's Range
77.2-79.4
52 wk Range
38.75-83.3
Volume
19.2K
Average Volume (3m)
21.23K
1-Year Change
45.0467%
Book Value / Share
7.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHNU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
83.33
Upside
+7.39%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 6 consecutive years

Pharmanutra SpA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 83.33
(+7.39% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 17, 2026
EPS / Forecast
0,62 / --
Revenue / Forecast
37,1M / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.09%
Dividend Yield
1.55%
Industry Median 2.26%
Annualised payout
1.20
Paid annually
5-Years Growth
+12.36%
Growth Streak

PHNU Income Statement

Compare PHNU to Peers and Sector

Metrics to compare
PHNU
Peers
Sector
Relationship
P/E Ratio
37.0x17.6x11.9x
PEG Ratio
1.790.520.03
Price/Book
10.4x2.4x1.5x
Price / LTM Sales
5.6x1.3x0.9x
Upside (Analyst Target)
10.1%15.0%21.9%
Fair Value Upside
Unlock11.2%10.8%Unlock

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports. The company also sells instrumentation and software for body bioimpedance analysis through agents, distributors, and online sales. Pharmanutra S.p.A. was founded in 2000 and is headquartered in Pisa, Italy.

Employees
128
Market
Italy

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
871,92K9,11%67,57M
Other Institutional Investors
294,37K3,07%22,81M
Public Companies & Retail Investors
8,41M87,82%651,69M
Total
9,58M100,00%742,08M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Norges Bank Investment Management3,49%334 57525 930
Joh. Berenberg, Gossler & Co. KG0,93%88 8196 883

FAQ

What Is the Pharmanutra (PHNU) Stock Price Today?

The Pharmanutra stock price today is 77,60 EUR.

What Stock Exchange Does Pharmanutra Trade On?

Pharmanutra is listed and trades on the Milan Stock Exchange.

What Is the Stock Symbol for Pharmanutra?

The stock symbol for Pharmanutra is "PHNU."

Does Pharmanutra Pay Dividends? What’s The Current Dividend Yield?

The Pharmanutra dividend yield is 1.55%.

What Is the Pharmanutra Market Cap?

As of today, Pharmanutra market cap is 744,95M EUR.

What Is Pharmanutra's Earnings Per Share (TTM)?

The Pharmanutra EPS (TTM) is 2,09.

When Is the Next Pharmanutra Earnings Date?

Pharmanutra will release its next earnings report on May 11, 2026.

From a Technical Analysis Perspective, Is PHNU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Pharmanutra Stock Split?

Pharmanutra has split 0 times.

How Many Employees Does Pharmanutra Have?

Pharmanutra has 128 employees.

What is the current trading status of Pharmanutra (PHNU)?

As of May 08, 2026, Pharmanutra (PHNU) is trading at a price of 77,60 EUR, with a previous close of 77,50 EUR. The stock has fluctuated within a day range of 77,20 EUR to 79,40 EUR, while its 52-week range spans from 38,75 EUR to 83,30 EUR.

What Is Pharmanutra (PHNU) Price Target According to Analysts?

The average 12-month price target for Pharmanutra is 83,33 EUR, with a high estimate of 89 EUR and a low estimate of 76 EUR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +7,39% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.